Shopping Cart 0
Cart Subtotal
USD 0

Metered Dose Inhaler Devices - Medical Devices Pipeline Assessment, 2018

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2500

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 5000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 7500
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Metered Dose Inhaler Devices-Medical Devices Pipeline Assessment, 2018

Summary

GlobalData's Medical Devices sector report, Metered Dose Inhaler Devices-Medical Devices Pipeline Assessment, 2018 provides an overview of Metered Dose Inhaler Devices currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Metered Dose Inhaler Devices pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

- Extensive coverage of the Metered Dose Inhaler Devices under development

- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities

- The report reviews the major players involved in the development of Metered Dose Inhaler Devices and list all their pipeline projects

- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage

- The report provides key clinical trial data of ongoing trials specific to pipeline products

- Recent developments in the segment / industry

Reasons to buy

The report enables you to-

- Formulate significant competitor information, analysis, and insights to improve R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of Metered Dose Inhaler Devices under development

- Develop market-entry and market expansion strategies

- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline

- In-depth analysis of the product's current stage of development, territory and estimated launch date

READ MORE

Table Of Content

Scope

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 5

1.2 List of Figures 6

2 Introduction 7

2.1 Metered Dose Inhaler Devices Overview 7

3 Products under Development 8

3.1 Metered Dose Inhaler Devices-Pipeline Products by Stage of Development 8

3.2 Metered Dose Inhaler Devices-Pipeline Products by Territory 9

3.3 Metered Dose Inhaler Devices-Pipeline Products by Regulatory Path 10

3.4 Metered Dose Inhaler Devices-Pipeline Products by Estimated Approval Date 11

3.5 Metered Dose Inhaler Devices-Ongoing Clinical Trials 12

4 Metered Dose Inhaler Devices-Pipeline Products under Development by Companies 13

4.1 Metered Dose Inhaler Devices Companies-Pipeline Products by Stage of Development 13

4.2 Metered Dose Inhaler Devices-Pipeline Products by Stage of Development 14

5 Metered Dose Inhaler Devices Companies and Product Overview 15

5.1 Aerophase Inc Company Overview 15

5.2 AstraZeneca Plc Company Overview 16

5.3 Bespak Europe Ltd Company Overview 17

5.4 Chiesi Farmaceutici SpA Company Overview 18

5.5 Circassia Pharmaceuticals Plc Company Overview 19

5.6 Globe Medical Tech Inc (Inactive) Company Overview 23

5.7 Lab Automate Technologies Inc Company Overview 24

5.8 Medicom Innovation Partner a/s Company Overview 25

5.9 Min USA LLC Company Overview 26

5.10 Pearl Therapeutics Inc Company Overview 27

5.11 Reciprocal Labs Corp Company Overview 31

5.12 Rensselaer Polytechnic Institute Company Overview 32

5.13 Vectura Group Plc Company Overview 33

5.14 Verona Pharma Plc Company Overview 35

6 Metered Dose Inhaler Devices- Recent Developments 36

6.1 Jun 01, 2018: Vectura Group Appoints Anne Whitaker As Non-Executive Director 36

6.2 May 22, 2018: Circassia Announces Positive Data Presented at 2018 American Thoracic Society Conference from Tudorza Phase IV and Duaklir Phase III Studies 36

6.3 May 17, 2018: New England Journal of Medicine Publishes two Trials for Symbicort as an Anti-inflammatory Reliever Therapy 'as Needed' in Mild Asthma 37

6.4 May 16, 2018: Novartis announces changes to the Executive Committee 38

6.5 May 16, 2018: At the Meet Novartis Management investor event, Novartis highlights strategy to focus the company and drive sustainable growth 39

6.6 May 14, 2018: Mylan and West Virginia University Join Forces to Inspire West Virginia Youth Through STEM-CARE 41

6.7 May 10, 2018: Novartis India reconstitutes Board appoints Milan Paleja as Vice Chairman Managing Director 42

6.8 May 09, 2018: Mylan Reports First Quarter 2018 Results and Reaffirms 2018 Guidance 43

6.9 May 01, 2018: Merck Announces First-Quarter 2018 Financial Results 45

6.10 Apr 26, 2018: Consort Medical: Director Declaration 49

6.11 Apr 25, 2018: Novartis launches FocalView app, providing opportunity for patients to participate in ophthalmology clinical trials from home 49

6.12 Apr 25, 2018: Boehringer Ingelheim has a very successful 2017 financial year 50

6.13 Apr 20, 2018: Vectura Announces Senior Management Change 51

6.14 Apr 20, 2018: Vectura Group: Directorate Change-Chief Financial Officer 51

6.15 Apr 20, 2018: Mylan Lays off around 500 Morgantown Employees 52

6.16 Apr 19, 2018: Novartis delivered a strong first quarter and acted to become a more focused medicines company 52

6.17 Apr 19, 2018: Novartis appoints John Tsai Head of Global Drug Development and Chief Medical Officer 56

6.18 Apr 11, 2018: Investor Day Highlights Durability of Mylan's Global Platform 57

6.19 Mar 21, 2018: Vectura Group: 2017 Preliminary Results 58

6.20 Mar 21, 2018: Vectura Group: 2017 Preliminary Results-Performance in-line with expectations, with strong in-market growth from key inhaled products 59

6.21 Mar 20, 2018: Merck Names Jennifer Zachary As General Counsel 60

6.22 Mar 12, 2018: Novartis announces changes to the Executive Committee to support strategic priorities 61

6.23 Feb 28, 2018: Mylan Reports Full Year and Fourth Quarter 2017 Results and Provides 2018 Guidance 62

6.24 Feb 26, 2018: 16-Year Veteran Director Wendy Cameron to Retire from Mylan Board after 2018 AGM 63

6.25 Feb 12, 2018: AVITA Medical Announces FDA Approval Of Expansion Of RECELL Compassionate Use Program In Life Threatening Injuries 64

6.26 Feb 12, 2018: Boehringer Ingelheim Demonstrates their Commitment to Site Relationships by Joining SCRS' Global Impact Partner Program 65

6.27 Feb 10, 2018: MagForce USA Receives FDA Investigational Device Exemption Approval to Conduct A Clinical Trial With NanoTherm Therapy As Focal Ablation Treatment For Intermediate Risk Prostate Cancer 65

6.28 Feb 09, 2018: Novartis layoffs to start in April at closing Broomfield plant 66

6.29 Feb 08, 2018: Propeller Health Achieves ISO 13485 Medical Device Quality Certification 67

6.30 Jan 31, 2018: Boehringer Ingelheim Announces Paul Fonteyne to Retire at the end of 2018. Wolfgang Baiker Appointed U.S. President & CEO Effective March 1, 2018. 67

6.31 Jan 29, 2018: Novartis India Appoints Jawed Zia As Vice Chairman And Managing Director 68

6.32 Jan 24, 2018: Merck Names Inge Thulin To Board Of Directors 68

7 Appendix 115

7.1 Methodology 115

7.2 About GlobalData 118

7.3 Contact Us 118

7.4 Disclaimer 118


List Of Figure

1.2 List of Figures

Figure 1: Metered Dose Inhaler Devices-Pipeline Products by Stage of Development 8

Figure 2: Metered Dose Inhaler Devices-Pipeline Products by Territory 9

Figure 3: Metered Dose Inhaler Devices-Pipeline Products by Regulatory Path 10

Figure 4: Metered Dose Inhaler Devices-Pipeline Products by Estimated Approval Date 11

Figure 5: Metered Dose Inhaler Devices-Ongoing Clinical Trials 12


List Of Table

1.1 List of Tables

Table 1: Metered Dose Inhaler Devices-Pipeline Products by Stage of Development 8

Table 2: Metered Dose Inhaler Devices-Pipeline Products by Territory 9

Table 3: Metered Dose Inhaler Devices-Pipeline Products by Regulatory Path 10

Table 4: Metered Dose Inhaler Devices-Pipeline Products by Estimated Approval Date 11

Table 5: Metered Dose Inhaler Devices-Ongoing Clinical Trials 12

Table 6: Metered Dose Inhaler Devices Companies-Pipeline Products by Stage of Development 13

Table 7: Metered Dose Inhaler Devices-Pipeline Products by Stage of Development 14

Table 8: Aerophase Inc Pipeline Products & Ongoing Clinical Trials Overview 15

Table 9: Metered Dose Inhaler-Product Status 15

Table 10: Metered Dose Inhaler-Product Description 15

Table 11: AstraZeneca Plc Pipeline Products & Ongoing Clinical Trials Overview 16

Table 12: Bevespi Aerosphere Inhalation Aerosol-Product Status 16

Table 13: Bevespi Aerosphere Inhalation Aerosol-Product Description 16

Table 14: Bespak Europe Ltd Pipeline Products & Ongoing Clinical Trials Overview 17

Table 15: VAL310 Easifill Valve-Product Status 17

Table 16: VAL310 Easifill Valve-Product Description 17

Table 17: Chiesi Farmaceutici SpA Pipeline Products & Ongoing Clinical Trials Overview 18

Table 18: Trimbow-Product Status 18

Table 19: Trimbow-Product Description 18

Table 20: Circassia Pharmaceuticals Plc Pipeline Products & Ongoing Clinical Trials Overview 19

Table 21: Fliveo-Product Status 19

Table 22: Fliveo-Product Description 19

Table 23: Fluticasone propionate/Salmeterol xinafoate pMDI-Product Status 20

Table 24: Fluticasone propionate/Salmeterol xinafoate pMDI-Product Description 20

Table 25: Circassia Pharmaceuticals Plc-Ongoing Clinical Trials Overview 21

Table 26: Fluticasone propionate/Salmeterol xinafoate pMDI-A Phase III Registration Study of Seretide Substitute (PSX2005) 22

Table 27: Globe Medical Tech Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 23

Table 28: Inhaler-Product Status 23

Table 29: Inhaler-Product Description 23

Table 30: Lab Automate Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 24

Table 31: Ultrasonic Metered Dose Inhaler-Product Status 24

Table 32: Ultrasonic Metered Dose Inhaler-Product Description 24

Table 33: Medicom Innovation Partner a/s Pipeline Products & Ongoing Clinical Trials Overview 25

Table 34: Asmair-Product Status 25

Table 35: Asmair-Product Description 25

Table 36: Min USA LLC Pipeline Products & Ongoing Clinical Trials Overview 26

Table 37: Envi-Product Status 26

Table 38: Envi-Product Description 26

Table 39: Pearl Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview 27

Table 40: PT001-Product Status 27

Table 41: PT001-Product Description 27

Table 42: PT010-Product Status 28

Table 43: PT010-Product Description 28

Table 44: Pearl Therapeutics Inc-Ongoing Clinical Trials Overview 29

Table 45: PT010-A Randomized, Double-blind, Multi-center, Parallel-group Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 on COPD Exacerbations Over a 52-Week Treatment Period in Subjects with Moderate to Very Severe COPD: Ethos 30

Table 46: Reciprocal Labs Corp Pipeline Products & Ongoing Clinical Trials Overview 31

Table 47: Connected Metered Dose Inhaler-Product Status 31

Table 48: Connected Metered Dose Inhaler-Product Description 31

Table 49: Rensselaer Polytechnic Institute Pipeline Products & Ongoing Clinical Trials Overview 32

Table 50: Bloom Inhaler-Product Status 32

Table 51: Bloom Inhaler-Product Description 32

Table 52: Vectura Group Plc Pipeline Products & Ongoing Clinical Trials Overview 33

Table 53: Flutiform K-Haler-Product Status 33

Table 54: Flutiform K-Haler-Product Description 33

Table 55: Flutiform pMDI-Product Status 34

Table 56: Flutiform pMDI-Product Description 34

Table 57: Verona Pharma Plc Pipeline Products & Ongoing Clinical Trials Overview 35

Table 58: RPL554-Metered Dose Inhaler-Product Status 35

Table 59: RPL554-Metered Dose Inhaler-Product Description 35

Table 60: Glossary 117

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Aerophase Inc, Metered Dose Inhaler; AstraZeneca Plc, Bevespi Aerosphere Inhalation Aerosol; Bespak Europe Ltd, VAL310 Easifill Valve; Chiesi Farmaceutici SpA, Trimbow; Circassia Pharmaceuticals Plc, Fliveo; Circassia Pharmaceuticals Plc, Fluticasone propionate/Salmeterol xinafoate pMDI; Globe Medical Tech Inc (Inactive), Inhaler; Lab Automate Technologies Inc, Ultrasonic Metered Dose Inhaler; Medicom Innovation Partner a/s, Asmair; Min USA LLC, Envi; Pearl Therapeutics Inc, PT001; Pearl Therapeutics Inc, PT010; Reciprocal Labs Corp, Connected Metered Dose Inhaler; Rensselaer Polytechnic Institute, Bloom Inhaler; Vectura Group Plc, Flutiform K-Haler; Vectura Group Plc, Flutiform pMDI; Verona Pharma Plc, RPL554 - Metered Dose Inhaler


Companies

Aerophase Inc

AstraZeneca Plc

Bespak Europe Ltd

Chiesi Farmaceutici SpA

Circassia Pharmaceuticals Plc

Globe Medical Tech Inc

Lab Automate Technologies Inc

Medicom Innovation Partner a/s

Min USA LLC

Pearl Therapeutics Inc

Reciprocal Labs Corp

Rensselaer Polytechnic Institute

Vectura Group Plc

Verona Pharma Plc

Metered Dose Inhaler Devices-Medical Devices Pipeline Assessment, 2018

Summary

GlobalData's Medical Devices sector report, Metered Dose Inhaler Devices-Medical Devices Pipeline Assessment, 2018 provides an overview of Metered Dose Inhaler Devices currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Metered Dose Inhaler Devices pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

- Extensive coverage of the Metered Dose Inhaler Devices under development

- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities

- The report reviews the major players involved in the development of Metered Dose Inhaler Devices and list all their pipeline projects

- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage

- The report provides key clinical trial data of ongoing trials specific to pipeline products

- Recent developments in the segment / industry

Reasons to buy

The report enables you to-

- Formulate significant competitor information, analysis, and insights to improve R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of Metered Dose Inhaler Devices under development

- Develop market-entry and market expansion strategies

- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline

- In-depth analysis of the product's current stage of development, territory and estimated launch date

READ MORE

Scope

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 5

1.2 List of Figures 6

2 Introduction 7

2.1 Metered Dose Inhaler Devices Overview 7

3 Products under Development 8

3.1 Metered Dose Inhaler Devices-Pipeline Products by Stage of Development 8

3.2 Metered Dose Inhaler Devices-Pipeline Products by Territory 9

3.3 Metered Dose Inhaler Devices-Pipeline Products by Regulatory Path 10

3.4 Metered Dose Inhaler Devices-Pipeline Products by Estimated Approval Date 11

3.5 Metered Dose Inhaler Devices-Ongoing Clinical Trials 12

4 Metered Dose Inhaler Devices-Pipeline Products under Development by Companies 13

4.1 Metered Dose Inhaler Devices Companies-Pipeline Products by Stage of Development 13

4.2 Metered Dose Inhaler Devices-Pipeline Products by Stage of Development 14

5 Metered Dose Inhaler Devices Companies and Product Overview 15

5.1 Aerophase Inc Company Overview 15

5.2 AstraZeneca Plc Company Overview 16

5.3 Bespak Europe Ltd Company Overview 17

5.4 Chiesi Farmaceutici SpA Company Overview 18

5.5 Circassia Pharmaceuticals Plc Company Overview 19

5.6 Globe Medical Tech Inc (Inactive) Company Overview 23

5.7 Lab Automate Technologies Inc Company Overview 24

5.8 Medicom Innovation Partner a/s Company Overview 25

5.9 Min USA LLC Company Overview 26

5.10 Pearl Therapeutics Inc Company Overview 27

5.11 Reciprocal Labs Corp Company Overview 31

5.12 Rensselaer Polytechnic Institute Company Overview 32

5.13 Vectura Group Plc Company Overview 33

5.14 Verona Pharma Plc Company Overview 35

6 Metered Dose Inhaler Devices- Recent Developments 36

6.1 Jun 01, 2018: Vectura Group Appoints Anne Whitaker As Non-Executive Director 36

6.2 May 22, 2018: Circassia Announces Positive Data Presented at 2018 American Thoracic Society Conference from Tudorza Phase IV and Duaklir Phase III Studies 36

6.3 May 17, 2018: New England Journal of Medicine Publishes two Trials for Symbicort as an Anti-inflammatory Reliever Therapy 'as Needed' in Mild Asthma 37

6.4 May 16, 2018: Novartis announces changes to the Executive Committee 38

6.5 May 16, 2018: At the Meet Novartis Management investor event, Novartis highlights strategy to focus the company and drive sustainable growth 39

6.6 May 14, 2018: Mylan and West Virginia University Join Forces to Inspire West Virginia Youth Through STEM-CARE 41

6.7 May 10, 2018: Novartis India reconstitutes Board appoints Milan Paleja as Vice Chairman Managing Director 42

6.8 May 09, 2018: Mylan Reports First Quarter 2018 Results and Reaffirms 2018 Guidance 43

6.9 May 01, 2018: Merck Announces First-Quarter 2018 Financial Results 45

6.10 Apr 26, 2018: Consort Medical: Director Declaration 49

6.11 Apr 25, 2018: Novartis launches FocalView app, providing opportunity for patients to participate in ophthalmology clinical trials from home 49

6.12 Apr 25, 2018: Boehringer Ingelheim has a very successful 2017 financial year 50

6.13 Apr 20, 2018: Vectura Announces Senior Management Change 51

6.14 Apr 20, 2018: Vectura Group: Directorate Change-Chief Financial Officer 51

6.15 Apr 20, 2018: Mylan Lays off around 500 Morgantown Employees 52

6.16 Apr 19, 2018: Novartis delivered a strong first quarter and acted to become a more focused medicines company 52

6.17 Apr 19, 2018: Novartis appoints John Tsai Head of Global Drug Development and Chief Medical Officer 56

6.18 Apr 11, 2018: Investor Day Highlights Durability of Mylan's Global Platform 57

6.19 Mar 21, 2018: Vectura Group: 2017 Preliminary Results 58

6.20 Mar 21, 2018: Vectura Group: 2017 Preliminary Results-Performance in-line with expectations, with strong in-market growth from key inhaled products 59

6.21 Mar 20, 2018: Merck Names Jennifer Zachary As General Counsel 60

6.22 Mar 12, 2018: Novartis announces changes to the Executive Committee to support strategic priorities 61

6.23 Feb 28, 2018: Mylan Reports Full Year and Fourth Quarter 2017 Results and Provides 2018 Guidance 62

6.24 Feb 26, 2018: 16-Year Veteran Director Wendy Cameron to Retire from Mylan Board after 2018 AGM 63

6.25 Feb 12, 2018: AVITA Medical Announces FDA Approval Of Expansion Of RECELL Compassionate Use Program In Life Threatening Injuries 64

6.26 Feb 12, 2018: Boehringer Ingelheim Demonstrates their Commitment to Site Relationships by Joining SCRS' Global Impact Partner Program 65

6.27 Feb 10, 2018: MagForce USA Receives FDA Investigational Device Exemption Approval to Conduct A Clinical Trial With NanoTherm Therapy As Focal Ablation Treatment For Intermediate Risk Prostate Cancer 65

6.28 Feb 09, 2018: Novartis layoffs to start in April at closing Broomfield plant 66

6.29 Feb 08, 2018: Propeller Health Achieves ISO 13485 Medical Device Quality Certification 67

6.30 Jan 31, 2018: Boehringer Ingelheim Announces Paul Fonteyne to Retire at the end of 2018. Wolfgang Baiker Appointed U.S. President & CEO Effective March 1, 2018. 67

6.31 Jan 29, 2018: Novartis India Appoints Jawed Zia As Vice Chairman And Managing Director 68

6.32 Jan 24, 2018: Merck Names Inge Thulin To Board Of Directors 68

7 Appendix 115

7.1 Methodology 115

7.2 About GlobalData 118

7.3 Contact Us 118

7.4 Disclaimer 118


List Of Figure

1.2 List of Figures

Figure 1: Metered Dose Inhaler Devices-Pipeline Products by Stage of Development 8

Figure 2: Metered Dose Inhaler Devices-Pipeline Products by Territory 9

Figure 3: Metered Dose Inhaler Devices-Pipeline Products by Regulatory Path 10

Figure 4: Metered Dose Inhaler Devices-Pipeline Products by Estimated Approval Date 11

Figure 5: Metered Dose Inhaler Devices-Ongoing Clinical Trials 12


List Of Table

1.1 List of Tables

Table 1: Metered Dose Inhaler Devices-Pipeline Products by Stage of Development 8

Table 2: Metered Dose Inhaler Devices-Pipeline Products by Territory 9

Table 3: Metered Dose Inhaler Devices-Pipeline Products by Regulatory Path 10

Table 4: Metered Dose Inhaler Devices-Pipeline Products by Estimated Approval Date 11

Table 5: Metered Dose Inhaler Devices-Ongoing Clinical Trials 12

Table 6: Metered Dose Inhaler Devices Companies-Pipeline Products by Stage of Development 13

Table 7: Metered Dose Inhaler Devices-Pipeline Products by Stage of Development 14

Table 8: Aerophase Inc Pipeline Products & Ongoing Clinical Trials Overview 15

Table 9: Metered Dose Inhaler-Product Status 15

Table 10: Metered Dose Inhaler-Product Description 15

Table 11: AstraZeneca Plc Pipeline Products & Ongoing Clinical Trials Overview 16

Table 12: Bevespi Aerosphere Inhalation Aerosol-Product Status 16

Table 13: Bevespi Aerosphere Inhalation Aerosol-Product Description 16

Table 14: Bespak Europe Ltd Pipeline Products & Ongoing Clinical Trials Overview 17

Table 15: VAL310 Easifill Valve-Product Status 17

Table 16: VAL310 Easifill Valve-Product Description 17

Table 17: Chiesi Farmaceutici SpA Pipeline Products & Ongoing Clinical Trials Overview 18

Table 18: Trimbow-Product Status 18

Table 19: Trimbow-Product Description 18

Table 20: Circassia Pharmaceuticals Plc Pipeline Products & Ongoing Clinical Trials Overview 19

Table 21: Fliveo-Product Status 19

Table 22: Fliveo-Product Description 19

Table 23: Fluticasone propionate/Salmeterol xinafoate pMDI-Product Status 20

Table 24: Fluticasone propionate/Salmeterol xinafoate pMDI-Product Description 20

Table 25: Circassia Pharmaceuticals Plc-Ongoing Clinical Trials Overview 21

Table 26: Fluticasone propionate/Salmeterol xinafoate pMDI-A Phase III Registration Study of Seretide Substitute (PSX2005) 22

Table 27: Globe Medical Tech Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 23

Table 28: Inhaler-Product Status 23

Table 29: Inhaler-Product Description 23

Table 30: Lab Automate Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 24

Table 31: Ultrasonic Metered Dose Inhaler-Product Status 24

Table 32: Ultrasonic Metered Dose Inhaler-Product Description 24

Table 33: Medicom Innovation Partner a/s Pipeline Products & Ongoing Clinical Trials Overview 25

Table 34: Asmair-Product Status 25

Table 35: Asmair-Product Description 25

Table 36: Min USA LLC Pipeline Products & Ongoing Clinical Trials Overview 26

Table 37: Envi-Product Status 26

Table 38: Envi-Product Description 26

Table 39: Pearl Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview 27

Table 40: PT001-Product Status 27

Table 41: PT001-Product Description 27

Table 42: PT010-Product Status 28

Table 43: PT010-Product Description 28

Table 44: Pearl Therapeutics Inc-Ongoing Clinical Trials Overview 29

Table 45: PT010-A Randomized, Double-blind, Multi-center, Parallel-group Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 on COPD Exacerbations Over a 52-Week Treatment Period in Subjects with Moderate to Very Severe COPD: Ethos 30

Table 46: Reciprocal Labs Corp Pipeline Products & Ongoing Clinical Trials Overview 31

Table 47: Connected Metered Dose Inhaler-Product Status 31

Table 48: Connected Metered Dose Inhaler-Product Description 31

Table 49: Rensselaer Polytechnic Institute Pipeline Products & Ongoing Clinical Trials Overview 32

Table 50: Bloom Inhaler-Product Status 32

Table 51: Bloom Inhaler-Product Description 32

Table 52: Vectura Group Plc Pipeline Products & Ongoing Clinical Trials Overview 33

Table 53: Flutiform K-Haler-Product Status 33

Table 54: Flutiform K-Haler-Product Description 33

Table 55: Flutiform pMDI-Product Status 34

Table 56: Flutiform pMDI-Product Description 34

Table 57: Verona Pharma Plc Pipeline Products & Ongoing Clinical Trials Overview 35

Table 58: RPL554-Metered Dose Inhaler-Product Status 35

Table 59: RPL554-Metered Dose Inhaler-Product Description 35

Table 60: Glossary 117

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

Aerophase Inc, Metered Dose Inhaler; AstraZeneca Plc, Bevespi Aerosphere Inhalation Aerosol; Bespak Europe Ltd, VAL310 Easifill Valve; Chiesi Farmaceutici SpA, Trimbow; Circassia Pharmaceuticals Plc, Fliveo; Circassia Pharmaceuticals Plc, Fluticasone propionate/Salmeterol xinafoate pMDI; Globe Medical Tech Inc (Inactive), Inhaler; Lab Automate Technologies Inc, Ultrasonic Metered Dose Inhaler; Medicom Innovation Partner a/s, Asmair; Min USA LLC, Envi; Pearl Therapeutics Inc, PT001; Pearl Therapeutics Inc, PT010; Reciprocal Labs Corp, Connected Metered Dose Inhaler; Rensselaer Polytechnic Institute, Bloom Inhaler; Vectura Group Plc, Flutiform K-Haler; Vectura Group Plc, Flutiform pMDI; Verona Pharma Plc, RPL554 - Metered Dose Inhaler


Companies

Aerophase Inc

AstraZeneca Plc

Bespak Europe Ltd

Chiesi Farmaceutici SpA

Circassia Pharmaceuticals Plc

Globe Medical Tech Inc

Lab Automate Technologies Inc

Medicom Innovation Partner a/s

Min USA LLC

Pearl Therapeutics Inc

Reciprocal Labs Corp

Rensselaer Polytechnic Institute

Vectura Group Plc

Verona Pharma Plc